{"summary": "a therapeutic antibody against the viral envelope (E) protein represents a promising immunotherapy for disease control. mAbs were further dissected using recombinant E protein domain I-II (E-DI-II) and III (E-DIII) of DENV-2. mAb DB32-6 was the strongest neutralizing mAb against diverse DENV-2 strains. 500,000 cases of dengue hemorrhagic fever (DHF) occur every year. 2.5 billion people are at risk of dengue infection globally. dengue infection may lead to fever, headache and joint pain in milder cases. studies of the biological characteristics and epitope specificities of mouse monoclonal antibodies have elucidated the antigenic structure of flavivirus E proteins. serotype-specific mAbs with neutralizing activity against DENV-2 have been found to be located on the lateral ridge of E-DIII. the subcomplex-specific mAbs recognized A-strand of E-DIII [14], [16], [17] two mAbs recognized the A-strand of E-DIII at residues K310 and E311 respectively. humanized DB32-6 mAb effectively neutralized DENV-2 infection in a therapeutic mouse model. female 4- to 6-week-old mice were immunized with 107 plaque-forming units (pfu) of DENV-2 (16681) the spleen was harvested and then fused with mouse myeloma NS-1 cells. mAbs were affinity-purified by standard protein G-Sepharose 4 Fast Flow. western blot analysis C6/36 cells were harvested after viral infection. cells were incubated with peroxidase substrate o-phenylenediamine dihydrochloride (OPD; Sigma-Aldrich) the expression constructs of E-DI-II and E-DIII were cloned into the pET21a vector (Merck) the recombinant proteins E-DI-II and E-DIII were analyzed using 12% SDS-PAGE by Western blot analysis. antibody-virus mixtures (100 l) were added to BHK-21 cells at 80%\u201390% confluency in 12-well plates. after absorption of virus for 2 h, BHK-21 cells were washed and 2 ml of 1% (w/v) carboxyl methyl cellulose (Sigma-Aldrich) in MEM plus 2% (v/v) FBS was layered onto infected cells. cells were incubated with 4G2 at a concentration of 1 g/ml at 4\u00b0C for 30 min. mice were killed with 50% CO2 containing 50% O2. survival rate and signs of illness were observed daily for 21 days. antibodies (100 g per mouse, intraperitoneally) were administered 1 day before infection. in postexposure therapeutic experiments, antibodies (100 g per mouse, intraperitoneally) were administered on day 1, 3, 5 and 7 after infection. amplified phage diluted 5-fold was added to coated plate and incubated at RT for 1 h. OPD developed and was terminated with HCl. mutants were generated by site-directed mutagenesis. mAbs total RNA was extracted from hybridoma cells using the TRIzol reagent (Invitrogen) Purified mRNA was reverse transcribed using oligo (dT) as a primer in a ThermoScript RT-PCR system (Invitrogen) the cDNA product was cloned using a variety of primer sets. humanized DB32-6 VH consisted of modified FRs from the accession DI084180 gene and the CDR1 to CDR3 of the DB32-6 VL. both were synthesized (GENEART) and amplified by PCR using pfu Turbo DNA polymerase. the resulting VH was cloned into modified expression vector pcDNA3.1 (Invitrogen) the mAbs were injected at a flow rate of 30 l/min for 3 min. the mAbs were then allowed to dissociate over 1.5 min. the data were analyzed by the BIAevaluation software. paired t-test was used to determine the significant differences. cells and viruses BHK-21 cells were grown at 37\u00b0C with 5% CO2. female 4- to 6-week-old mice were immunized with 107 plaque-forming units (pfu) of DENV-2 (16681) the spleen was harvested and then fused with mouse myeloma NS-1 cells. mAbs were affinity-purified by standard protein G-Sepharose 4 Fast Flow. cells were incubated with peroxidase substrate o-phenylenediamine dihydrochloride (OPD; Sigma-Aldrich) cell extracts were mixed with sample buffer. nonspecific antibody-binding sites were blocked with 5% skimmed milk. the expression constructs of E-DI-II and E-DIII were cloned into the pET21a vector (Merck) the E-DI-II, comprising amino acids 1\u2013295 of the E protein, was tagged to flag and hexahistidine. antibody-virus mixtures (100 l) were added to BHK-21 cells at 80%\u201390% confluency in 12-well plates. after absorption, BHK-21 cells were washed and 2 ml of 1% (w/v) carboxyl methyl cellulose (Sigma-Aldrich) in MEM plus 2% (v/v) FBS was layered onto the infected cells. cells were incubated with 4G2 at a concentration of 1 g/ml at 4\u00b0C for 30 min. mice were killed with 50% CO2 containing 50% O2. survival rate and signs of illness were observed daily for 21 days. antibodies (100 g per mouse, intraperitoneally) were administered 1 day before infection. antibodies (100 g per mouse, intraperitoneally) were administered on day 1, 3, 5 and 7 after infection. amplified phage diluted 5-fold was added to coated plate and incubated at RT for 1 h. OPD developed and was terminated with HCl. mutants were generated by site-directed mutagenesis. mRNA was reverse transcribed using oligo (dT) as a primer in a ThermoScript RT-PCR system (Invitrogen) Purified mRNA was reverse transcribed using oligo (dT) as a primer in a ThermoScript RT-PCR system (Invitrogen) humanized DB32-6 VH consisted of modified FRs from the accession DI084180 gene and the CDR1 to CDR3 of the DB32-6 VH. both were synthesized (GENEART) and amplified by PCR using pfu Turbo DNA polymerase. the resulting VH was cloned into modified expression vector pcDNA3.1 (Invitrogen) with a signal peptide and human IgG1 constant region the mAbs were injected at a flow rate of 30 l/min for 3 min. the mAbs were then allowed to dissociate over 1.5 min. the data were analyzed by the BIAevaluation software. survival rate was expressed using Kaplan-Meier survival curve. log rank test was used to determine the significant differences. paired t-test was used to determine the significant differences. three mAbs (DB21-6, DB22-4 and DB36-2) recognized E protein. C6/36 cells were infected with DENV-1, -2, -3 and -4. protein samples were dissolved in native sample buffer and fractionated by 10% SDS-PAGE. mAbs by IFA, ELISA, WB and PRNT50 (g/ml) mAbs Isotype, Light chain Specificity IFA ELISA PRNT50 (g/ml) E-DIII + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 10 mAbs targeted to E-DI-II and 2 mAbs recognized E-DIII. but 5 mAbs could not be identified by these two assays. mAb DB32-6 was found to be a DENV-2 serotype-specific mAb against E-DIII. many complex reactive mAbs showed moderate-to-poor neutralizing activity. neutrifying activity of DENV-2 mAbs and DB32-6 showed therapeutic efficacy in Stat1/ mice. antibodies (100 g per mouse, i.p.) were administered on day 1, 1, 3, 5 and 7 after infection (D left). mAbs DB32-6 at a concentration of 10 g/ml protected 93% of the mice from the lethal challenge of DENV-2. mAb DB32-6 showed a significant delay of the onset of paralysis and death relative to the NMIgG. survival rates for DB32-6 at 100 g/ml or 1 g/ml were 100% and 89%, respectively. in comparison, 3H5 showed 82% and 40% survival rates at 100 g/ml. mAb DB32-6 exhibited effective neutralization against various DENV-2 strains. phage titers increased to 85-fold (DB32-6) and 331-fold (DB25-2) compared to phage display biopanning results. ELISA reactivity of selected phage clones with DB32-6 and DB25-2. consensus amino acids of DB32-6 and DB25-2 epitopes are marked in gray. 17 immunopositive phage clones that were highly reactive with DB32-6 were amplified. strand of E-DIII was changed to alanine (K310A) or glutamine (K310Q) in the A-strand of E-DIII. mAb 3H5 recognized residues K305, E383 and P384. epitopes in the A-strand of E-DIII were important for inducing neutralizing antibodies. the native E protein consisted of three domains designated DI (red), DII (yellow) and DIII (blue) the native E protein is a homodimer on the surface of the virus. the serotype-specific neutralizing epitopes located in E-DIII were K310 (green) and E311 (purple) mAb hDB32-6-48 was dose-dependent against DENV-2 and E-DIII. the affinity was analyzed by surface plasmon resonance. hDB32-6 maintained the same binding affinity to the E protein as mDB32-6. mAb hDB32-6 and hDB32-6 protected mice from deNV-2-induced mortality. mAbs, mDB32-6 and hDB32-6-6-48, protected against deNV-2-induced mice mortality. modification of Fc structure in an antibody can prevent Fc receptors binding. the hDB32-6 variant retained the same neutralizing activity as unmodified mAb mDB32-6 at high concentrations (100 g/ml and 10 g/ml) but was completely devoid of enhancing activity at low concentrations. a pan-flavivirus mAb that could recognize the fusion loop of E-DI-II, and 3H5 (ATCC HB46) was a DENV-2 serotype-specific mAb that could recognize the lateral ridge of E-DIII [12], [17], [40]. the specificities of the mAbs recognized as the four DENVs were further confirmed by ELISA and Western blotting. protein samples were dissolved in native sample buffer and fractionated by 10% SDS-PAGE. mAbs recognized E protein (53 kDa) of DENV. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Western blot analysis and IFA showed that 10 mAbs targeted to E-DI-II and 2 mAbs recognized E-DIII. 5 mAbs could not be identified by these two assays. mAb DB32-6 was found to be a DENV-2 serotype-specific mAb against E-DIII. it could completely inhibit the infection at a lower concentration of 1.2 g/ml. mAb DB25-2 was found to be a DENV-2 serotype-specific mAb against E-DIII. two-day-old suckling mice (ICR strain) were challenged intracranially (i.c.) with the mAb:DENV-2 mixture. Mice were observed daily for signs of illness including paralysis for 21 days. mAbs DB32-6 at a concentration of 10 g/ml protected 93% of the mice from the lethal challenge of DENV-2. mAbs 3H5, DB23-3, DB2-3 and DB25-2 had survival rates of 75%, 76%, 72% and 71% respectively. mAb DB32-6 exhibited effective neutralization against different DENV-2 strains. mAb DB32-6 exhibited effective neutralization against different DENV-2 strains. phage display biopanned the phage after three rounds of phage display. titers increased to 85-fold (DB32-6) and 331-fold (DB25-2) compared to the phage display biopanning results from the first round. individual phage clones from the third round of biopanning were randomly selected. ELISA was performed to determine whether the mAbs could specifically recognize selected phage clones. phage-displayed peptide sequences selected by DB32-6 had consensus motifs of histidine (H)-lysine (K)-glutamic acid (E)-tryptophan (W)/tyrosine (Y)-histidine (H). 17 immunopositive phage clones selected by DB32-6 using phage library displayed 7 amino acid residues, which contained the consensus motif H-K-E-W/Y-H we found residues K310 and E311 in E-DIII of different genotypes. epitopes in the A-strand of E-DIII were important for inducing neutralizing antibodies. mAbs hDB32-6-30, hDB32-6-48 and hDB32-6-51 were found to have high binding activity. mAbs hDB32-6-30, hDB32-6-48 and hDB32-6-51 were found to have high binding activity. three stable clones of hDB32-6 (hDB32-6-30, hDB32-6-48 and hDB32-6-51) recognized DENV-2-infected C6/36 cells and recombinant E-DIII of DENV-2 by ELISA. mAb hDB32-6 protected mice from DENV-2-induced mortality. two-day-old suckling mice (ICR strain) were injected intracranially (i.c.) with 1104 pfu of DENV-2 (16681) after 1 day of infection, 5 g of mAb were passively injected into mice through an i.c. route. mAb hDB32-6 variant eliminate ADE phenomenon. antibody-mediated enhancement of DENV-2 infection by mAbs. 17 mAbs with high reactivity against E protein of DENV-2. mAb DB32-6 was humanized and modified to abrogate ADE. mAb DB32-6 is a serotype-specific neutralizing mAb that recognized residue K310 but not residues K305 or K307. mAb DB32-6 is a serotype-specific neutralizing mAb that recognized residue K305, K307 and K310 in A-strand [15], [17]. complex-specific epitope, DB32-6 is a serotype-specific mAb. by mutating residue I312, DB32-6's binding activity was reduced by 50%. Residue I312 may be a minor epitope of DB32-6. de Alwis et al. has conducted an in-depth analysis of the human mAbs derived from memory B-cells of patients infected with primary DENV infections. mAbs that cross-react with other flaviviruses are in E-DII near the fusion loop, which is immunodominant antigenic [20], [34], [42]. studies that explore the mAbs mediated neutralization mechanism and mAbs dependent enhancement are currently underway. the mouse models for dengue infection developed to date do not represent the entirety of the pathogenesis of human dengue infection. mAbs recognized DENV-2 (16681) infected BHK-21 cells by immunofluorescence assay. at 48 hours post-inoculation, antigen was detected by mAbs to DENV-2, followed by staining with FITC conjugated goat anti-mouse IgG antibodies (green). cells were counterstained with DAPI (blue) and examined under fluorescence microscopy. serial dilutions of DB32-6 mAb were incubated with DENV-2 (16681, NGC, PL046 and Malaysia 07587) after 2 days infection, the percentages of infected cells were assessed by flow cytometry. K310 (green) and E311 (purple) are recognized by DB32-6 and DB25-2 respectively. table S1 The database, gene/protein and accession/ID number were mentioned in the text."}